Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin Pharmaceutical (BMRN – Research Report), Harmony Biosciences Holdings (HRMY – Research Report) and Cronos Group (CRON – Research Report).
BioMarin Pharmaceutical (BMRN)
In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $185.00. The company’s shares closed last Tuesday at $81.45, close to its 52-week low of $80.14.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
Currently, the analyst consensus on BioMarin Pharmaceutical is a Moderate Buy with an average price target of $110.91, which is a 37.2% upside from current levels. In a report issued on October 25, Piper Sandler also maintained a Buy rating on the stock with a $125.00 price target.
See today’s best-performing stocks on TipRanks >>
Harmony Biosciences Holdings (HRMY)
In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Harmony Biosciences Holdings, with a price target of $28.00. The company’s shares closed last Tuesday at $23.54, close to its 52-week low of $18.61.
According to TipRanks.com, Gerberry is a 1-star analyst with an average return of
Harmony Biosciences Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $42.00.
Cronos Group (CRON)
In a report released yesterday, Lisa Lewandowski from Bank of America Securities reiterated a Sell rating on Cronos Group, with a price target of $1.55. The company’s shares closed last Tuesday at $1.81, close to its 52-week low of $1.64.
Lewandowski has an average return of
According to TipRanks.com, Lewandowski is ranked #724 out of 8565 analysts.
Currently, the analyst consensus on Cronos Group is a Hold with an average price target of $2.47.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BMRN:
- BMRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pinterest upgraded, Salesforce downgraded: Wall Street’s top analyst calls
- BioMarin upgraded to Market Perform from Underperform at Bernstein
- BioMarin reports FDA approves expanded indication for Voxzogo
- BioMarin initiated with a Market Perform at Raymond James
